REGENXBIO Inc. opened its new Manufacturing Innovation Center gene therapy manufacturing facility at its 132,000 sq.-ft. headquarters in Rockville, MD.    The state-of-the-art good manufacturing practice (GMP) facility will enable the company to boost manufacturing of NAV Technology-based adeno-associated virus (AAV) vectors at scales up to 2,000 liters. The facility will implement REGENXBIO’s NAVXpress™ platform suspension cell culture process, which has demonstrated the ability to incr...